Validation of pharmacogenomic biomarker classifiers for treatment selection

Cancer Biomarkers

Volumn 2, Issue 3-4, 2006, Pages 89-96

  Simon, Richard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

biomarker; clinical trial design; DNA microarray; genomics; Pharmacogenomics; validation

Indexed keywords

BIOLOGICAL MARKER; NEW DRUG;

CLASSIFICATION; HUMAN; METHODOLOGY; PHARMACOGENETICS; PREDICTION AND FORECASTING; REVIEW; VALIDATION STUDY;

BIOLOGICAL MARKERS; DRUGS, INVESTIGATIONAL; HUMANS; PHARMACOGENETICS; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN;

EID: 34548702653     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2006-23-402     Document Type: Article

References (15)

1. FDA. Draft guidance for industry: Pharmacogenomics data submission. Rockville MD: Food and Drug Administration; 2003.
2. B. Freidlin and R. Simon, Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients, Clinical Cancer Research (2005), in Press.
3. A. Maitournam and R. Simon, On the efficiency of targeted clinical trials, Statistics in Medicine 24 (2005), 329-339.
4. S. Michiels, S. Koscielny and C. Hill, Prediction of cancer outcome with microarrays: a multiple random validation strategy, The Lancet 365, 488-492.
5. A.M. Molinaro, R. Simon and R.M. Pfeiffer, Prediction error estimation: A comparison of resampling methods, Bioinformatics 21 (2005), 3301-3307.
6. S. Paik, S. Shak, G. Tang, C. Kim, J. Baker, M. Cronin et al., A multigene assay to predict recurrence of tamoxifentreated, node-negative breast cancer, New England Journal of Medicine 351 (2004), 2817-2826.
7. L. Pusztai and K.R. Hess, Clinical trial design for microarray predictive marker discovery and assessment, Annals of Oncology 15 (2004), 1731-1737.
8. M.D. Radmacher, L.M. McShane and R. Simon, A paradigm for class prediction using gene expression profiles, Journal of Computational Biology 9 (2002), 505-511.
9. A. Rosenwald, G. Wright, W.C. Chan, J.M. Connors, E. Campo, R.I. Fisher et al., The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma, New England Journal of Medicine 346 (2002), 1937-1947.
10. D.J. Sargent, B.A. Conley, C. Allegra and L. Collette, Clinical trial designs for predictive marker validation in cancer treatment trials, Journal of Clinical Oncology 23 (2005), 2020-2027.
11. R. Simon and D.G. Altman, Statistical aspects of prognostic factor studies in oncology, British Journal of Cancer 69 (1994), 979-985.
12. R. Simon and A.P. Lam, BRB-ArrayTools Users Guide (Version 3.3), Bethesda MD: Biometric Research Branch National Cancer Institute; 2005. Report No.: Technical Report 28, http://linus.nci.nih.gob/brb.
13. R. Simon and A. Maitournam, Evaluating the efficiency of targeted designs for randomized clinical trials, Clinical Cancer Research 10 (2004), 6759-6763.
14. R. Simon, M.D. Radmacher, K. Dobbin and L.M. McShane, Pitfalls in the analysis of DNA microarray data: Class prediction methods, Journal of the National Cancer Institute 95 (2003), 14-18.
15. R.M. Simon, E.L. Korn, L.M. McShane, M.D. Radmacher, G.W. Wright and Y. Zhao, Design and analysis of DNA microarray investigations, New York: Springer; 2003.